The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate: A Randomized, Placebo-Controlled, Crossover Study in Healthy Subjects
Open accessAbstract
Background—: Rivaroxaban and dabigatran are new oral anticoagulants that specifically inhibit factor Xa and thrombin, respectively. Clinical studies on the prevention and treatment of venous and arterial thromboembolism show promising results. A major disadvantage of these anticoagulants is the absence of an antidote in case of serious bleeding or when an emergency intervention needs immediate correction of coagulation. This study evaluated the potential of prothrombin complex concentrate (PCC) to reverse the anticoagulant effect of these drugs. Methods and Results—: In a randomized, double-blind, placebo-controlled study, 12 healthy male volunteers received rivaroxaban 20 mg twice daily (n=6) or dabigatran 150 mg twice daily (n=6) for 2½ days, followed by either a single bolus of 50 IU/kg PCC (Cofact) or a similar volume of saline. After a washout period, this procedure was repeated with the other anticoagulant treatment. Rivaroxaban induced a significant prolongation of the prothrombin time (15.8±1.3 versus 12.3±0.7 seconds at baseline; P <0.001) that was immediately and completely reversed by PCC (12.8±1.0; P <0.001). The endogenous thrombin potential was inhibited by rivaroxaban (51±22%; baseline, 92±22%; P =0.002) and normalized with PCC (114±26%; P <0.001), whereas saline had no effect. Dabigatran increased the activated partial thromboplastin time, ecarin clotting time (ECT), and thrombin time. Administration of PCC did not restore these coagulation tests. Conclusion—: Prothrombin complex concentrate immediately and completely reverses the anticoagulant effect of rivaroxaban in healthy subjects but has no influence on the anticoagulant action of dabigatran at the PCC dose used in this study. Clinical Trial Registration—: URL: http://www.trialregister.nl . Unique identifier: NTR2272.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007903 · Cited by 3,237
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
Schulman, S., Kearon, C., Kakkar, A. K., Mismetti, P., Schellong, S., Eriksson, H., Baanstra, D., Schnee, J., & Goldhaber, S. Z. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0906598 · Cited by 2,583
Pharmacology and Management of the Vitamin K Antagonists
Ansell, J., Hirsh, J., Hylek, E., Jacobson, A., Crowther, M., & Palareti, G. (2008) · Chest · doi:10.1378/chest.08-0670 · Cited by 2,118
Calibrated Automated Thrombin Generation Measurement in Clotting Plasma
Hemker, H. C., Giesen, P., Al Dieri, R., Regnault, V., de Smedt, E., Wagenvoord, R., Lecompte, T., & Béguin, S. (2003) · Pathophysiology of Haemostasis and Thrombosis · doi:10.1159/000071636 · Cited by 1,430
Stangier, J., Haertter, S., Liesenfeld, K.-H., Wienen, W., Feuring, M., Clemens, A., & Ryn, J. V. (2010) · Thrombosis and Haemostasis · doi:10.1160/th09-11-0758 · Cited by 1,382
Stangier, J. (2008) · Clinical Pharmacokinetics · doi:10.2165/00003088-200847050-00001 · Cited by 655
Kubitza, D., Becka, M., Wensing, G., Voith, B., & Zuehlsdorf, M. (2005) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-005-0043-5 · Cited by 640
Leissinger, C. A., Blatt, P. M., Hoots, W. K., & Ewenstein, B. (2008) · American Journal of Hematology · doi:10.1002/ajh.21046 · Cited by 353
Bijsterveld, N. R., Moons, A. H., Boekholdt, S. M., van Aken, B. E., Fennema, H., Peters, R. J. G., Meijers, J. C. M., Büller, H. R., & Levi, M. (2002) · Circulation · doi:10.1161/01.cir.0000038501.87442.02 · Cited by 316
Self-citationPłusa, T. (2012) · Journal of Health Policy & Outcomes Research · doi:10.7365/jhpor.2012.1.1 · Cited by 298
Stangier, J., Eriksson, B. I., Dahl, O. E., Ahnfelt, L., Nehmiz, G., Stähle, H., Rathgen, K., & Svärd, R. (2005) · The Journal of Clinical Pharmacology · doi:10.1177/0091270005274550 · Cited by 296
Rivaroxaban: A New Oral Factor Xa Inhibitor
Perzborn, E., Roehrig, S., Straub, A., Kubitza, D., Mueck, W., & Laux, V. (2010) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.110.202978 · Cited by 276
Kubitza, D., Becka, M., Zuehlsdorf, M., & Mueck, W. (2006) · The Journal of Clinical Pharmacology · doi:10.1177/0091270006286904 · Cited by 254
Stassen, J.-M., Priepke, H., Ries, U. J., Hauel, N., & Wienen, W. (2007) · Thrombosis and Haemostasis · doi:10.1160/th07-03-0183 · Cited by 250
Friedman, R. J., Dahl, O. E., Rosencher, N., Caprini, J. A., Kurth, A. A., Francis, C. W., Clemens, A., Hantel, S., Schnee, J. M., & Eriksson, B. I. (2010) · Thrombosis Research · doi:10.1016/j.thromres.2010.03.021 · Cited by 141
Graff, J., von Hentig, N., Misselwitz, F., Kubitza, D., Becka, M., Breddin, H., & Harder, S. (2007) · The Journal of Clinical Pharmacology · doi:10.1177/0091270007302952 · Cited by 139
Managing bleeding in anticoagulated patients with a focus on novel therapeutic agents
Crowther, M. A., & Warkentin, T. E. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03429.x · Cited by 98
Cao, Y. B., Zhang, J. D., Shen, H., & Jiang, Y. Y. (2010) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-010-0889-z · Cited by 72
Prothrombin Complex Concentrate Reverses the Effects of High-Dose Rivaroxaban in Rats
Perzborn, E., Trabandt, A., Selbach, K., & Tinel, H. (2009) · Cited by 33
Beriplex P/N reverses bleeding in an acute renal injury model after dabigatran overdose in rabbits
Pragst, I., Dörr, B., Kaspereit, F., et al. (2012) · F1000Research · doi:10.7490/f1000research.1089950.1 · Cited by 13
Cited by
Roffi, M., Patrono, C., Collet, J.-P., Mueller, C., Valgimigli, M., Andreotti, F., Bax, J. J., Borger, M. A., Brotons, C., Chew, D. P., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv320 · Cited by 8,261
Hemphill, J. C., Greenberg, S. M., Anderson, C. S., Becker, K., Bendok, B. R., Cushman, M., Fung, G. L., Goldstein, J. N., Macdonald, R. L., Mitchell, P. H., et al. (2015) · Stroke · doi:10.1161/str.0000000000000069 · Cited by 3,994
2012 focused update of the ESC Guidelines for the management of atrial fibrillation
Authors/Task Force Members, Camm, A. J., Lip, G. Y. H., De Caterina, R., Savelieva, I., Atar, D., Hohnloser, S. H., Hindricks, G., Kirchhof, P., ESC Committee for Practice Guidelines (CPG), et al. (2012) · EP Europace · doi:10.1093/europace/eus305 · Cited by 3,822
2012 focused update of the ESC Guidelines for the management of atrial fibrillation
Authors/Task Force Members, Camm, A. J., Lip, G. Y. H., De Caterina, R., Savelieva, I., Atar, D., Hohnloser, S. H., Hindricks, G., Kirchhof, P., ESC Committee for Practice Guidelines (CPG), et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs253 · Cited by 2,899
Joglar, J. A., Chung, M. K., Armbruster, A. L., Benjamin, E. J., Chyou, J. Y., Cronin, E. M., Deswal, A., Eckhardt, L. L., Goldberger, Z. D., Gopinathannair, R., et al. (2024) · Circulation · doi:10.1161/cir.0000000000001193 · Cited by 2,765
Metadata
- Authors
- Eerenberg, E. S., Kamphuisen, P. W., Sijpkens, M. K., Meijers, J. C., Buller, H. R., & Levi, M.
- Venue
- Circulation
- Published
- 2011-10-04
- Volume
- 124
- Issue
- 14
- Pages
- 1573-1579
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2481569543
- Cited by
- 1,361
- References
- 21
- FWCI
- 135.63
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.